Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01962792 · ClinicalTrials.gov registry record · Phase 1
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01962792: Completed Phase 1 study, sponsored by Pharmacyclics.
NCT01962792 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01962792, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Primary Outcome
-To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
What the finished NCT01962792 record still lists
NCT01962792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01962792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01962792 about?
NCT01962792 is a clinical study titled "Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma". A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
What is the current status of trial NCT01962792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2013-12. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01962792?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT01962792?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01962792's enrollment target sits among peer trials
84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia